VECTURA (VEC)

 

VEC Share PerformanceMore

52 week high200.10 12/01/16
52 week low140.00 17/02/15
52 week change 30.00 (20.00%)
4 week volume13,073,118 11/01/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - Numis issues a broker note on Vectura Group PLC

Numis today reaffirms its buy investment rating on Vectura Group PLC (LON:VEC) and set its price target at 271p.

Total Voting Rights

RNS Number: 6239N Vectura Group plc 01 February 2016 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 1 February 2016: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: Th...

Broker Forecast - Peel Hunt issues a broker note on Vectura Group PLC

Peel Hunt today reaffirms its buy investment rating on Vectura Group PLC (LON:VEC) and raised its price target to 279p...

Share of the week: Investors rush to this safe haven

While equity values collapse elsewhere, one mining company's share price has risen to its highest in over two months. Mark...

Vectura says VR315 US completes clinical study

Vectura Group confirms the completion of a clinical trial for VR315 in the US. VR315 is a generic, inhaled combination th...

VR315 US completes clinical study

RNS Number: 2222L Vectura Group plc 08 January 2016 Vectura Group plc VR315 US completes clinical study Chippenham, UK - 8 January 2016: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces the completion of a clinical trial for VR315 in the US. VR315 is a generic, inhaled combination therapy ( fluticasone/salmeterol) for asthma/COPD...

Total Voting Rights

RNS Number: 6968K Vectura Group plc 04 January 2016 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 4 January 2016: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: The...

Vectura delight as Ablynx completes trial enrolment

Vectura Group is delighted that Ablynx has confirmed it has completed target enrolment of the first-in-infant phase I/IIa ...

Fundamental DataMore

P/E ratio200
EPS0.9
Dividend yield0 %

Latest discussion posts More

  • Numis reiterate 271p target

    Numis have today reiterated their Buy and 271p target: Http://www.risersandfallers.com/2016/02/04/vectura-group-plc-reiterated-as-buy-by-numis/
    4-Feb-2016
    gretel
  • - Vectura results singer ups

    www.bing.com/news/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=DB9B05EBE0794147BB93C50B2F39F48A&url=http%3a%2f%2fzolmax.com%2finvesting%2fvectu ...
    29-Jan-2016
    d gaser
  • Novartis - Vectura results

    RESPIRATORY Q4/15 Q4/14 %change FY/15 FY/14 % change Ultibro Breezhaler 76 51 ...
    28-Jan-2016
    Ambiorix1

Users' HoldingsMore

Users who hold VECTURA also hold..
LLOYDS GRP.26%
VODAFONE GRP.20%
BP20%
GLAXOSMITHKLINE16%
NATIONAL GRID16%

Codes & Symbols

ISINGB00B01D1K48
SymbolsVEC, LSE:VEC, VEC.L, VEC:LN, LON:VEC, XLON:VEC